Equities

Shanghai Medicilon Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Shanghai Medicilon Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)66.45
  • Today's Change-0.74 / -1.10%
  • Shares traded2.00m
  • 1 Year change+104.46%
  • Beta2.2149
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Shanghai Medicilon Inc is a China-based company principally engaged in providing comprehensive preclinical research and development services for biopharmaceuticals. The Company's services mainly include drug discovery, pharmaceutical research and preclinical research. Drug discovery research and development services include protein target validation, structural biology, chemical synthesis, compound activity screening and optimization. Pharmaceutical research includes active pharmaceutical ingredients and formulation process research, quality standards and stability research. Preclinical research includes pharmacodynamics, pharmacokinetics, toxicology and safety evaluation research. The Company mainly operates its businesses in the domestic and overseas markets.

  • Revenue in CNY (TTM)1.08bn
  • Net income in CNY-231.86m
  • Incorporated2004
  • Employees2.27k
  • Location
    Shanghai Medicilon IncNo. 585 Chuanda Road, Pudong New AreaSHANGHAI 201299ChinaCHN
  • Phone+86 2 158591500
  • Fax+86 2 158596369
  • Websitehttps://www.medicilon.com.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shanghai Aladdin Biochemical Tech Co Ltd599.98m83.95m5.28bn652.0063.824.95--8.790.24850.24851.783.210.27850.42184.55920,216.305.047.816.908.6062.2160.6118.0924.951.539.150.354148.3332.4420.5515.079.1741.61--
Hangzhou Alltest Biotech Co Ltd881.63m294.76m5.41bn969.0018.331.39--6.143.723.7211.1249.210.20982.386.39909,839.107.0219.187.5721.6655.0057.7933.4738.828.34--0.009335.1414.8329.1367.5030.9971.01--
Bide Pharmatech Co Ltd1.27bn153.31m5.43bn738.0033.982.71--4.271.761.7614.4922.030.51670.88045.251,720,520.006.247.027.528.2943.3042.1612.0713.132.78--0.105548.730.929834.697.17--80.65--
Shouyao Holdings Co Ltd2.14m-206.73m5.78bn178.00--8.83--2,697.32-1.39-1.390.01444.400.00250.03660.262512,033.88-23.67-32.53-27.20-36.2595.7499.43-9,651.03-3,370.016.42--0.0044---24.61-19.34-14.21--49.71--
Jiangsu Yahong Meditech Co Ltd279.02m-362.17m6.84bn391.00--3.86--24.52-0.642-0.6420.49333.100.12511.164.19713,603.90-16.84-14.30-19.15-15.0172.2273.78-134.65-703.804.96--0.1545--1,365.55--4.09--50.48--
GemPharmatech Co Ltd752.70m121.51m6.98bn1.58k56.613.17--9.270.30070.30071.865.370.28074.511.88476,993.404.537.695.428.9661.8468.1716.1425.583.17--0.129521.9410.3928.94-30.8925.8820.02--
Beijing Sun-Novo Pharma Research Co Ltd1.02bn133.01m7.46bn1.36k54.876.42--7.341.211.219.2310.380.474535.481.28653,956.406.0411.3910.4918.8248.6053.3112.7219.661.789.970.335511.2915.7035.80-3.9830.213.50--
Shanghai Medicilon Inc1.08bn-231.86m8.93bn2.27k--4.33--8.27-1.75-1.758.0415.360.37598.561.68459,338.00-8.083.66-9.994.6316.2731.15-21.496.672.19--0.150840.97-24.0118.22-896.21--2.54--
Bio-Thera Solutions Ltd845.32m-368.84m9.81bn1.17k--20.27--11.61-0.8908-0.89082.041.170.37020.77225.96---16.15-16.38-33.76-22.2274.9977.05-43.63-62.110.4617-34.120.573--5.44302.90-29.34--11.14--
HitGen Inc498.51m114.11m11.80bn483.00104.308.02--23.670.28240.28241.243.670.27266.374.691,032,114.006.183.066.873.3655.2353.5522.6714.485.126.590.167434.3214.9910.0826.13-15.653.16--
InventisBio Co Ltd180.53m-116.28m12.73bn185.00--7.64--70.51-0.2012-0.20120.31222.880.0988--1.03975,824.70-6.36-32.89-6.76-35.2299.41---64.41-682.73----0.0127---9.0225.0015.41---3.97--
Data as of Feb 13 2026. Currency figures normalised to Shanghai Medicilon Inc's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

1.72%Per cent of shares held by top holders
HolderShares% Held
Huisheng Fund Management Co., Ltd.as of 30 Jun 2025407.65k0.37%
The Vanguard Group, Inc.as of 04 Feb 2026377.32k0.34%
Guotai Asset Management Co., Ltd.as of 30 Jun 2025342.63k0.31%
China Asset Management Co., Ltd.as of 30 Jun 2025190.36k0.17%
CCB Principal Asset Management Co., Ltd.as of 30 Jun 2025134.44k0.12%
E Fund Management Co., Ltd.as of 30 Jun 2025129.03k0.12%
Wanjia Asset Management Co., Ltd.as of 30 Jun 2025122.00k0.11%
Zhong Ou Asset Management Co., Ltdas of 30 Jun 202568.20k0.06%
Dimensional Fund Advisors LPas of 05 Feb 202659.98k0.06%
New China Fund Management Co., Ltd.as of 30 Jun 202558.87k0.05%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.